HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer

Journal of Internal Medicine

Volumn 260, Issue 5, 2006, Pages 484-487

  Inui, T ^a   Asakawa, A ^a   Morita, Y ^b   Mizuno, S ^c   Natori, T ^d   Kawaguchi, A ^b   Murakami, M ^b   Hishikawa, Y ^b   Inui, A ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SRL INC   (Japan)

Author keywords

Gastric cancer; HER 2 overexpression; Personalized therapy; Proton ion beam; Trastuzumab

Indexed keywords

CAPECITABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; TRASTUZUMAB;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ESOPHAGOGASTRODUODENOSCOPY; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER METASTASIS; MALE; ONCOGENE NEU; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON RADIATION; STOMACH BIOPSY; STOMACH CANCER;

ADENOCARCINOMA; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 33750023455     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01715.x     Document Type: Article

References (14)

1. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19: 554-68.
2. Barnard J. Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology. Gastroenterology 2001; 120: 1872-4.
3. Mann M, Sheng H, Shao J et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120: 1713-9.
4. Yonemura Y, Ninomiya I, Yamaguchi A et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-38.
5. Inui A. Targeted therapy in cancer and transgenic animal model. Cancer Invest 2003; 21: 819-20.
6. Kapitanovic S, Radosevic S, Kapitanovic M et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-13.
7. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
8. van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. J Clin Oncol 2003; 21: 2234-6.
9. Rebischung C, Barnoud R, Stefani L et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 2005; 8: 249-52.
10. Kagawa K, Murakami M, Hishikawa Y et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. Int J Radiat Oncol Biol Phys 2002; 54: 928-38.
11. Weyrather WK, Debus J. Particle beams for cancer therapy. Clin Oncol (R Coll Radiol) 2003; 15: S23-8.
12. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
14. Kaklamani V, O'regan RM. New targeted therapies in breast cancer. Semin Oncol 2004; 31: 20-5.